Inactief instrument

Koers Biondvax Pharmaceuticals Ltd Other OTC

Aandelen

Duur

Periode

Stijl

Biondvax Pharmaceuticals : Announces Rights Offering Fully Subscribed at US$20 Million	16-07-19
Biondvax Pharmaceuticals : First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial	08-07-19
Biondvax Pharmaceuticals : European Investment Bank VP attends Signature Event at BiondVax Extending Financing Agreement with BiondVax to €24 million	26-06-19
Biondvax Pharmaceuticals : Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan	18-06-19
Biondvax Pharmaceuticals : Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process	10-06-19

Sector

	Vaira. 1 jan.	Kapi.
MODERNA, INC.	+55,55%	59,34 mld.
LONZA GROUP AG	+43,17%	40,24 mld.
IQVIA HOLDINGS INC.	-4,71%	39,88 mld.
CELLTRION, INC.	-5,56%	28,55 mld.
ICON PUBLIC LIMITED COMPANY	+13,76%	27,26 mld.
ALNYLAM PHARMACEUTICALS, INC.	-22,00%	19,23 mld.
MEDPACE HOLDINGS, INC.	+31,50%	12,61 mld.
BIO-TECHNE CORPORATION	+2,16%	12,49 mld.
UNITED THERAPEUTICS CORPORATION	+25,70%	12,28 mld.